Chief Financial Officer · PALVELLA THERAPEUTICS, INC. (PVLA)

Allan Reine

A named executive officer of PALVELLA THERAPEUTICS in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$871,262

Salary $386,250Stock awards $0Bonus $131,325

FY2017: $1,977,186

3rd of 3 named executive officers at Palvella Therapeutics by FY2018 total.

3 named officers on file for PALVELLA THERAPEUTICS, FY2018

Allan Reine’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how PALVELLA THERAPEUTICS’s whole pay program stands against its peers

  • PALVELLA THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PVLA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 18, 2019 (DEF 14A).

Free

Get Allan Reine’s full pay file as a PDF — free

More than this page: up to 10 years of Allan’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Allan Reine compensation by year

PALVELLA THERAPEUTICS Summary Compensation Table · all 2 fiscal years held
In US dollars, as PALVELLA THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$148,352$386,250
Bonus$150,000$131,325
Stock awards$0$0
Option awards$1,662,130$309,145
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$16,704$44,542
Total$1,977,186$871,262

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PALVELLA THERAPEUTICS, INC. DEF 14A filed June 18, 2019, accession 0001583648-19-000035, and prior-year filings. Open the filing on EDGAR.

How this page was built: the PALVELLA THERAPEUTICS, INC. filed document, accession 0001583648-19-000035. Every figure is read from that document and cited to the page and table it appears in. Filed June 18, 2019.

$2.0M
$871K
FY17
FY18
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option309,375—$5.00
Option50,000—$5.00
Option53,833—$8.56

Per the Outstanding Equity Awards at Fiscal Year-End table in PALVELLA THERAPEUTICS, INC.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

PALVELLA THERAPEUTICS’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Stephen YoderChief Executive Officer$2,621,008
Louis MatisChief Development Officer$1,124,169
Allan Reine · this pageChief Financial Officer$871,262

The full PALVELLA THERAPEUTICS compensation record

free company brief

This page is one person within PALVELLA THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are PALVELLA THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Allan Reine's compensation dossier · One-time report. No refunds.